The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
Francis A FarrayeTaha QaziPaulo Gustavo KotzeGregory T MooreRajiv MundayatNervin LawendyPuza P SharmaDonna T JuddPublished in: Alimentary pharmacology & therapeutics (2021)
Efficacy and safety of tofacitinib were similar in patients with UC regardless of baseline BMI.